GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » THC Therapeutics Inc (OTCPK:THCT) » Definitions » Operating Income

THC Therapeutics (THC Therapeutics) Operating Income

: $-0.50 Mil (TTM As of Jul. 2023)
View and export this data going back to 2007. Start your Free Trial

THC Therapeutics's Operating Income for the three months ended in Jul. 2023 was $-0.06 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jul. 2023 was $-0.50 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. THC Therapeutics's Operating Income for the three months ended in Jul. 2023 was $-0.06 Mil. THC Therapeutics's Revenue for the three months ended in Jul. 2023 was $0.00 Mil. Therefore, THC Therapeutics's Operating Margin % for the quarter that ended in Jul. 2023 was %.

THC Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. THC Therapeutics's annualized ROC % for the quarter that ended in Jul. 2023 was -16.74%. THC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was %.


THC Therapeutics Operating Income Historical Data

The historical data trend for THC Therapeutics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

THC Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Operating Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.26 -1.39 -0.94 -1.75 -0.49

THC Therapeutics Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Operating Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.11 -0.27 -0.06 -0.06

THC Therapeutics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


THC Therapeutics  (OTCPK:THCT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

THC Therapeutics's annualized ROC % for the quarter that ended in Jul. 2023 is calculated as:

ROC % (Q: Jul. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2023 ) + Invested Capital (Q: Jul. 2023 ))/ count )
=-0.22 * ( 1 - 0% )/( (1.335 + 1.293)/ 2 )
=-0.22/1.314
=-16.74 %

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

THC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2023  Q: Jul. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.052/( ( (0 + max(-2.457, 0)) + (0 + max(-2.49, 0)) )/ 2 )
=-0.052/( ( 0 + 0 )/ 2 )
=-0.052/0
= %

where Working Capital is:

Working Capital(Q: Apr. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.001) - (1.867 + 0.06 + 0.531)
=-2.457

Working Capital(Q: Jul. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.001) - (1.942 + 0.06 + 0.489)
=-2.49

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

THC Therapeutics's Operating Margin % for the quarter that ended in Jul. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jul. 2023 )/Revenue (Q: Jul. 2023 )
=-0.055/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


THC Therapeutics Operating Income Related Terms

Thank you for viewing the detailed overview of THC Therapeutics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


THC Therapeutics (THC Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11700 W Charleston Boulevard, No. 73, Las Vegas, NV, USA, 89135
Website
THC Therapeutics Inc is a United States-based company. It is focused on developing dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis. It will reduce the drying time for cannabis from 10-14 days down to less than 14 hours.
Executives
Hiro Tanaka director, officer: Vice President 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Smith Adrian J R director, officer: Chair of the Board 119 SPRINGLINE DRIVE, VERO BEACH FL 32963
Jamie Mann director, 10 percent owner, officer: CEO, CFO 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Eden Ho director, officer: CEO 701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX